In a strategic move to expand its oncology pipeline, Sino Biopharmaceutical has agreed to acquire LaNova Medicines in a deal valued at approximately US$950.9 M. Through the deal, Sino Biopharm picks up LaNova’s portfolio, which includes eight clinical-stage assets, notably LM-299 and LM-305. With a focus on antibody-drug conjugates and bispecific antibodies, LaNova’s pipeline enhances Sino Biopharm’s biologics capabilities and global competitiveness. The deal reinforces the company’s commitment to precision oncology and supports its long-term growth strategy as it accelerates innovation across high-need cancer indications.